-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
british genomics and Illumina have announced a new agreement that will allow them to deliver up to 300,000 whole genome equivalents over the next five years, with the option of increasing to 500,000.
The partnership was established in December 2018 on the basis of the success of the 100,000 Genome Project, which established agreements to solicit the consent of patients with rare genetic diseases and cancers, tissue sample requirements, standardized DNA sequencing, data analysis and reporting.
As part of the collaboration, samples from NHS patients with rare diseases and cancer types from England will be eligible for genome-wide sequencing to support diagnosis, inform and improve treatment pathways and ultimately improve outcomes, with the expectation that the number of eligible people with clinical adaptations will expand over time.
Samples will be made available through nhs genomic medicine services and a network of seven genomic laboratory centres in England, which will be established in 2018.
The project aims to achieve Health Minister Matt Hancock's ambition to analyse up to five million genomes, including genome-wide sequencing, by 2024 "to enable the UK to maintain its position as a global leader in genomics".
Health Secretary Nicola Blackwood explained: "Genomic medicine has great potential to improve the diagnosis and treatment of some of our deadliest diseases, helping patients live longer and healthier lives.she continued: "Our 100,000 genome programmes have led to changes in the lives of many patients, and this agreement between Genomics UK and Illumina is another transformative step towards the NHS becoming truly predictive, preventive and personalized. The
will be sequenced using NovaSeq 6000, BaseSpace Sequence Hub and Illumina analysis tools.
Last October, research and innovation uk announced a new 200 million pound project to sequence the genetic code of half a million people to better understand, diagnose, treat and prevent life-changing diseases, including cancer and dementia. （cyy123.com）
